20 Aug 2019
Board Appointment: Ian Johnson Appointed as Non-Executive Director

Guildford, UK – 20 August 2019: Ergomed plc, (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce that Ian Johnson will join the Board as a Non-Executive Director with immediate effect.

Ian has spent his business career in life sciences and has served on the boards of a number of public and private companies. He was founder and CEO of Biotrace International plc, a leading provider of rapid microbial testing systems. Biotrace was a listed company until its sale to 3M in December 2006. Ian was Non-Executive Chairman of Celsis Group Ltd from 2009 until 2015 and Chairman of Cyprotex plc, a CRO, which was acquired by Evotec AG in 2016. He was later Chairman of Quantum Pharma plc, which was acquired by Clinigen Group plc in 2017, and most recently Executive Chairman of Bioquell plc from 2016 until its acquisition by Ecolab Inc. in 2019.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: “We are pleased to welcome Ian to the Board. This appointment continues a series of measures we began more than a year ago to drive long term growth through a focus on our services business and to strengthen the Board and management team. Ian has spent his career in the life sciences industry and has a strong track record in building shareholder value. We look forward to his contributions as we continue towards our goal of building a leading independent global mid-tier CRO.”

Ian Johnson said: “It is particularly exciting to be joining Ergomed’s Board of Directors at the present time. Ergomed is a robust platform in the clinical services marketplace with its highly differentiated offering which combines specialist CRO services and pharmacovigilance. The Company has performed strongly in the recent period, is operating net cash positive and has no debt. I look forward to working with the Board as the Company continues to execute its planned strategy delivering on its clear potential for continued growth.”

Save as disclosed below, in relation to current and prior directorships, Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Ian Johnson’s appointment.

Mr Ian Roy Johnson, aged 66, has held the following directorships in the past five years:

Current Directorships:

  • Klenitise Ltd

Directorships in the past five years:

  • Development Bank of Wales PLC
  • MDH Defence Ltd
  • Quantum Pharma PLC
  • Biofortuna Ltd
  • Cyprotex PLC
  • Lumora Ltd
  • Celsis Group Ltd
  • Toximet Ltd
  • Bioxyquell Ltd
  • Bioquell UK Ltd
  • Bioquell SAS
  • Bioquell Global Logistics (Ireland) Ltd
  • Bioquell Inc
  • Bioquell Defence Inc
  • Bioquell Professional Services Inc
  • Bioquell Asia Pacific Pte Ltd
  • Bioquell Technology (Shenzhen) Ltd
  • Bioquell Technology Canada Ltd
  • Bioquell PLC

Companies that went into administration and where creditors lost money as a result of liquidation:

  • Pure Options Solutions – Administrators appointed on 30 November 2010. The estimated deficiency to investors and creditors was £4.49 million.
  • Toximet Limited – Administrators appointed on 17 November 2015. The estimated deficiency to investors and creditors was £0.83 million.




Ergomed plc  Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications – for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services – for Continental European enquiries Tel: +49 211 5292 5222
Anne Hennecke



About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes a full range of high-quality contract research and trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand. For further information, visit: https://ergomedplc.com.